Foundry Partners LLC Decreases Holdings in Evolent Health, Inc. (NYSE:EVH)

Foundry Partners LLC decreased its holdings in Evolent Health, Inc. (NYSE:EVH) by 39.4% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 215,325 shares of the technology company’s stock after selling 139,773 shares during the period. Foundry Partners LLC’s holdings in Evolent Health were worth $2,422,000 as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in EVH. Wellington Management Group LLP lifted its stake in Evolent Health by 12.8% in the third quarter. Wellington Management Group LLP now owns 12,595,459 shares of the technology company’s stock worth $356,200,000 after purchasing an additional 1,426,747 shares during the last quarter. Boston Partners boosted its holdings in Evolent Health by 92.0% during the 4th quarter. Boston Partners now owns 2,444,006 shares of the technology company’s stock valued at $27,097,000 after acquiring an additional 1,171,304 shares during the period. Norges Bank bought a new position in Evolent Health during the 4th quarter worth approximately $12,519,000. Harbor Capital Advisors Inc. increased its stake in Evolent Health by 90.1% in the 4th quarter. Harbor Capital Advisors Inc. now owns 803,211 shares of the technology company’s stock worth $9,036,000 after purchasing an additional 380,790 shares during the period. Finally, Brighton Jones LLC bought a new stake in Evolent Health in the fourth quarter valued at approximately $3,927,000.

Analyst Ratings Changes

EVH has been the subject of a number of recent analyst reports. UBS Group lowered their price target on shares of Evolent Health from $27.00 to $14.00 and set a “buy” rating for the company in a report on Thursday, January 16th. Canaccord Genuity Group cut their target price on Evolent Health from $23.00 to $16.00 and set a “buy” rating on the stock in a research note on Thursday, January 23rd. Stephens lowered their price target on Evolent Health from $16.00 to $12.00 and set an “equal weight” rating for the company in a research report on Tuesday, January 21st. Needham & Company LLC reiterated a “buy” rating and issued a $15.00 price objective on shares of Evolent Health in a research report on Friday, February 21st. Finally, Royal Bank of Canada decreased their target price on Evolent Health from $20.00 to $17.00 and set an “outperform” rating for the company in a report on Tuesday, January 14th. One equities research analyst has rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Evolent Health has a consensus rating of “Buy” and an average price target of $17.71.

Insider Activity at Evolent Health

In other news, Director Diane Holder purchased 2,735 shares of Evolent Health stock in a transaction that occurred on Thursday, March 6th. The stock was bought at an average price of $9.33 per share, with a total value of $25,517.55. Following the completion of the transaction, the director now directly owns 70,584 shares of the company’s stock, valued at approximately $658,548.72. The trade was a 4.03 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, President Daniel Joseph Mccarthy acquired 11,040 shares of the firm’s stock in a transaction that occurred on Thursday, March 6th. The stock was purchased at an average price of $9.01 per share, with a total value of $99,470.40. Following the completion of the acquisition, the president now owns 389,004 shares in the company, valued at $3,504,926.04. The trade was a 2.92 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders purchased a total of 74,000 shares of company stock valued at $666,315 in the last 90 days. Corporate insiders own 1.60% of the company’s stock.

Evolent Health Stock Down 1.0 %

NYSE:EVH opened at $9.98 on Friday. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.04 and a quick ratio of 1.04. The firm’s 50-day moving average price is $9.79 and its 200-day moving average price is $14.83. The company has a market capitalization of $1.16 billion, a PE ratio of -12.17 and a beta of 1.49. Evolent Health, Inc. has a 1-year low of $8.35 and a 1-year high of $33.63.

Evolent Health (NYSE:EVH) last announced its quarterly earnings data on Thursday, February 20th. The technology company reported $0.03 earnings per share for the quarter, missing analysts’ consensus estimates of $0.38 by ($0.35). Evolent Health had a positive return on equity of 5.73% and a negative net margin of 2.41%. The business had revenue of $646.54 million during the quarter, compared to analysts’ expectations of $650.92 million. On average, equities analysts predict that Evolent Health, Inc. will post 0.08 EPS for the current fiscal year.

Evolent Health Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.